LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, has installed its ground-breaking z-Movi® Cell Avidity Analyzer at INmune Bio (NASDAQ: INMB).
INmune Bio is a clinical stage biotechnology company developing new therapies that modulate the innate immune system to treat cancer and neurodegenerative diseases, such as Alzheimer's. Its Natural Killer Cell Priming Platform, INKmune® is a "pseudokine" which drives a patient's own natural killer (NK) cells to memory-type NK cells which kill persistent tumors that survive initial treatments.
INmune Bio is employing the z-Movi cell avidity analysis platform to demonstrate that the mechanism of action of the tumor-priming is the increase in NK cell:tumor cell avidity. Early data acquired by the z-Movi support their hypothesis that increased cell avidity enhances NK cell killing of tumor cells. This allows screening of batches of INKmune for potency and provides a potential biomarker of in vivo activity by measuring the tumor avidity of NK cells isolated from patients before and after INKmune treatment.
https://finance.yahoo.com/news/inmune-bio-acquires-lumicks-z-155300234.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.